Nucleoside transporters are widely expressed in ovarian carcinoma effusions

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 467-475

  Bock, Annika J ^a,b   Dong, Hiep Phuc ^a   Tropé, Claes G ^a,c   Staff, Anne Cathrine ^b,c   Risberg, Björn ^a   Davidson, Ben ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Effusions; Flow cytometry; Nucleoside transporters; Ovarian carcinoma

Indexed keywords

CARBOPLATIN; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; EPIRUBICIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 4; NUCLEOSIDE TRANSPORTER; PACLITAXEL; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA CELL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM EXUDATE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITIC FLUID; COHORT STUDIES; DISEASE-FREE SURVIVAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION; PROGNOSIS; TREATMENT OUTCOME;

EID: 84856702201     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1716-7     Document Type: Article

References (21)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. B Davidson 2001 Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature Anal Cell Pathol 23 107 128 12082292 1:STN:280:DC%2BD38zotlKhsg%3D%3D (Pubitemid 34621775)
3. SA Baldwin PR Beal SYM Yao AE King CE Cass JD Young 2004 The equilibrative nucleoside transporter family, SLC29 Pflügers Arch 447 735 743 12838422 10.1007/s00424-003-1103-2 1:CAS:528:DC%2BD2cXhtVygsbk%3D (Pubitemid 38241459)
4. VL Damaraju S Damaraju JD Young SA Baldwin J Mackey MB Sawyer CE Cass 2003 Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy Oncogene 22 7524 7536 14576856 10.1038/sj.onc.1206952 1:CAS:528:DC%2BD3sXotlaju7k%3D (Pubitemid 37487174)
5. CM Galmarini JR Mackey C Dumontet 2002 Nucleoside analogues and nucleobases in cancer treatment Lancet Oncol 3 415 424 12142171 10.1016/S1470-2045(02)00788-X 1:CAS:528:DC%2BD38Xls1Wisrw%3D (Pubitemid 36958272)
6. X Farré E Guillén-Gómez L Sánchez D Hardisson Y Plaza J Lloberas FJ Casado J Palacios M Pastor-Anglada 2004 Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors Int J Cancer 112 959 966 15386342 10.1002/ijc.20524 (Pubitemid 39507001)
7. G Ferrandina V Mey S Nannizzi S Ricciardi M Petrillo C Ferlini R Danesi G Scambia M Del Tacca 2010 Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer Cancer Chemother Pharmacol 65 679 686 19639316 10.1007/s00280-009-1073-y 1:CAS:528:DC%2BC3cXotVGrtg%3D%3D
8. HP Dong A Holth A Berner B Davidson B Risberg 2007 Flow cytometric immunphenotyping of epithelial cancer cells in effusions-technical considerations and pitfalls Cytometry B Clin Cytom 72 332 343 17226863 (Pubitemid 350194350)
9. B Davidson S Nielsen J Christensen P Asschenfeldt A Berner B Risberg P Johansen 2001 The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells Am J Surg Pathol 25 1405 1412 11684957 10.1097/00000478-200111000-00008 1:STN:280:DC%2BD3MngvFOrsA%3D%3D (Pubitemid 33022056)
10. HP Dong L Kleinberg B Davidson B Risberg 2008 Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry Nat Protoc 3 955 964 18546596 10.1038/nprot.2008.77 1:CAS:528:DC%2BD1cXmvVemtL8%3D (Pubitemid 351818684)
11. HP Dong A Holth L Kleinberg MG Ruud MB Elstrand CG Tropé B Davidson B Risberg 2009 Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters Am J Clin Pathol 132 756 762 19846818 10.1309/AJCPAVFA8J3KHPRS
12. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214 7459811 10.1002/1097-0142(19810101)47: 1<207::AID-CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D (Pubitemid 11167383)
13. SA Cannistra 2004 Cancer of the ovary N Engl J Med 351 2519 2529 15590954 10.1056/NEJMra041842 1:CAS:528:DC%2BD2cXhtVGksbbM (Pubitemid 39603165)
14. TA Yap CP Carden SB Kaye 2009 Beyond chemotherapy: targeted therapies in ovarian cancer Nat Rev Cancer 9 167 181 19238149 10.1038/nrc2583 1:CAS:528:DC%2BD1MXit1ans74%3D
15. B Lund OP Hansen K Theilade M Hansen JP Neijt 1994 Phase II study of gemcitabine (2', 2'-difluorodeoxycytidine) in previously treated ovarian cancer patients J Natl Cancer Inst 86 1530 1533 7932808 10.1093/jnci/86.20.1530 1:STN:280:DyaK2M%2FhvVehsQ%3D%3D (Pubitemid 24330217)
16. D Lorusso A Di Stefano F Fanfani G Scambia 2006 Role of gemcitabine in ovarian cancer treatment Ann Oncol 17 Suppl 5 v188 v194 16807454 10.1093/annonc/mdj979 (Pubitemid 43985232)
17. J Pfisterer M Plante I Vergote A du Bois H Hirte AJ Lacave U Wagner A Stähle G Stuart R Kimmig S Olbricht T Le J Emerich W Kuhn J Bentley C Jackisch H Lück J Rochon AH Zimmermann E Eisenhauer 2006 Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 4699 4707 16966687 10.1200/JCO.2006.06.0913 1:CAS:528:DC%2BD28XhtFynsr3O (Pubitemid 46630933)
18. B Davidson HP Dong A Berner J Christensen S Nielsen P Johansen M Bryne P Asschenfeldt B Risberg 2002 Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases A J Clin Pathol 118 85 92 10.1309/M877-QABM-D9GB-FJAX (Pubitemid 34734257)
19. M Pennycooke N Chaudary I Shuralyova Y Zhang IR Coe 2001 Differential expression of human nucleoside transporters in normal and tumor tissue Biochem Biophys Res Commun 280 951 959 11162617 10.1006/bbrc.2000.4205 1:CAS:528:DC%2BD3MXls1aksw%3D%3D (Pubitemid 32924526)
20. J Spratlin R Sangha D Glubrecht L Dabbagh JD Young C Dumontet C Cass R Lai JR Mackey 2004 The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 6956 6961 15501974 10.1158/1078-0432.CCR-04-0224 1:CAS:528:DC%2BD2cXpslGltbc%3D (Pubitemid 39383046)
21. R Maréchal JR Mackey R Lai P Demetter M Peeters M Polus CE Cass J Young I Salmon J Devière J van Laethem 2009 Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin Cancer Res 15 2913 2919 19318496 10.1158/1078-0432.CCR-08- 2080